New Adaptive Method for Phase I Trials in Oncology

Assessment of the maximum tolerated dose for a small sample of patients is the objective of phase I trials in oncology. We propose a new adaptive approach performing differentiation of each type of toxicity and their grades, definition of the dose‐limiting toxicity as a logical combination of toxici...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2008-06, Vol.83 (6), p.873-881
Main Authors: Meille, C, Gentet, JC, Barbolosi, D, André, N, Doz, F, Iliadis, A
Format: Article
Language:English
Subjects:
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Clinical Trials, Phase I as Topic - methods
Clinical Trials, Phase I as Topic - trends
Humans
Maximum Tolerated Dose
Medical Oncology - methods
Medical Oncology - trends
Medical sciences
Models, Biological
Pharmacology. Drug treatments
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3953-dd48e9cbca9d66377b7a1776e278f75a5126abb24ccc219a18190f4cd95ecd063
cites cdi_FETCH-LOGICAL-c3953-dd48e9cbca9d66377b7a1776e278f75a5126abb24ccc219a18190f4cd95ecd063
container_end_page 881
container_issue 6
container_start_page 873
container_title Clinical pharmacology and therapeutics
container_volume 83
creator Meille, C
Gentet, JC
Barbolosi, D
André, N
Doz, F
Iliadis, A
description Assessment of the maximum tolerated dose for a small sample of patients is the objective of phase I trials in oncology. We propose a new adaptive approach performing differentiation of each type of toxicity and their grades, definition of the dose‐limiting toxicity as a logical combination of toxicity events, modeling of the risk of toxic events as a function of the drug dose, and integration of individual covariates. An application study with retrospective data from a phase I Taxol pediatric trial revealed age as an influential covariate, allowing individualization of a patient's maximum tolerated dose. A simulation study illustrates the practice of sequential inclusion of patients, of constraints in the dose‐finding process and of trial stopping rules. The approach presented here allows quick maximum tolerated dose assessment with a small sample of patients and assists the design of phase I trials in oncology. Clinical Pharmacology & Therapeutics (2008); 83, 6, 873–881 doi:10.1038/sj.clpt.6100383
doi_str_mv 10.1038/sj.clpt.6100383
format article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1038_sj_clpt_6100383</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CPT6100383</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3953-dd48e9cbca9d66377b7a1776e278f75a5126abb24ccc219a18190f4cd95ecd063</originalsourceid><addsrcrecordid>eNqFj71PwzAQxS0EoqUwM4G8MKb1R2zHY1XxUanQDmW2HNuhqdIksgNV_3tSJbQj0-nd_d7dPQDuMRpjRJNJ2I5NUTdjjlEr6QUYYkZJxBlll2CIEJKRJJQPwE0I21bGMkmuwQALyQRO2BCQD7eHU6vrJv9x8N01m8rCrPJwtdHBwTlc-1wXAeYlXJamKqqvwy24ytqWu-vrCHy-PK9nb9Fi-TqfTReRoZLRyNo4cdKkRkvLORUiFRoLwR0RSSaYZphwnaYkNsYQLDVOsERZbKxkzljE6QhMur3GVyF4l6na5zvtDwojdUyvwlYd06s-fet47Bz1d7pz9sz3cVvgqQd0MLrIvC5NHk4cQTEXmMuWEx23zwt3-O-umq3W5xceOmepm2_vTta_-S8dtH1X</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>New Adaptive Method for Phase I Trials in Oncology</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Meille, C ; Gentet, JC ; Barbolosi, D ; André, N ; Doz, F ; Iliadis, A</creator><creatorcontrib>Meille, C ; Gentet, JC ; Barbolosi, D ; André, N ; Doz, F ; Iliadis, A</creatorcontrib><description>Assessment of the maximum tolerated dose for a small sample of patients is the objective of phase I trials in oncology. We propose a new adaptive approach performing differentiation of each type of toxicity and their grades, definition of the dose‐limiting toxicity as a logical combination of toxicity events, modeling of the risk of toxic events as a function of the drug dose, and integration of individual covariates. An application study with retrospective data from a phase I Taxol pediatric trial revealed age as an influential covariate, allowing individualization of a patient's maximum tolerated dose. A simulation study illustrates the practice of sequential inclusion of patients, of constraints in the dose‐finding process and of trial stopping rules. The approach presented here allows quick maximum tolerated dose assessment with a small sample of patients and assists the design of phase I trials in oncology. Clinical Pharmacology &amp; Therapeutics (2008); 83, 6, 873–881 doi:10.1038/sj.clpt.6100383</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1038/sj.clpt.6100383</identifier><identifier>PMID: 17957185</identifier><identifier>CODEN: CLPTAT</identifier><language>eng</language><publisher>New York, NY: Nature Publishing</publisher><subject>Antineoplastic Agents - administration &amp; dosage ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Clinical Trials, Phase I as Topic - methods ; Clinical Trials, Phase I as Topic - trends ; Humans ; Maximum Tolerated Dose ; Medical Oncology - methods ; Medical Oncology - trends ; Medical sciences ; Models, Biological ; Pharmacology. Drug treatments ; Retrospective Studies</subject><ispartof>Clinical pharmacology and therapeutics, 2008-06, Vol.83 (6), p.873-881</ispartof><rights>2008 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3953-dd48e9cbca9d66377b7a1776e278f75a5126abb24ccc219a18190f4cd95ecd063</citedby><cites>FETCH-LOGICAL-c3953-dd48e9cbca9d66377b7a1776e278f75a5126abb24ccc219a18190f4cd95ecd063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20467169$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17957185$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meille, C</creatorcontrib><creatorcontrib>Gentet, JC</creatorcontrib><creatorcontrib>Barbolosi, D</creatorcontrib><creatorcontrib>André, N</creatorcontrib><creatorcontrib>Doz, F</creatorcontrib><creatorcontrib>Iliadis, A</creatorcontrib><title>New Adaptive Method for Phase I Trials in Oncology</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Assessment of the maximum tolerated dose for a small sample of patients is the objective of phase I trials in oncology. We propose a new adaptive approach performing differentiation of each type of toxicity and their grades, definition of the dose‐limiting toxicity as a logical combination of toxicity events, modeling of the risk of toxic events as a function of the drug dose, and integration of individual covariates. An application study with retrospective data from a phase I Taxol pediatric trial revealed age as an influential covariate, allowing individualization of a patient's maximum tolerated dose. A simulation study illustrates the practice of sequential inclusion of patients, of constraints in the dose‐finding process and of trial stopping rules. The approach presented here allows quick maximum tolerated dose assessment with a small sample of patients and assists the design of phase I trials in oncology. Clinical Pharmacology &amp; Therapeutics (2008); 83, 6, 873–881 doi:10.1038/sj.clpt.6100383</description><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Clinical Trials, Phase I as Topic - methods</subject><subject>Clinical Trials, Phase I as Topic - trends</subject><subject>Humans</subject><subject>Maximum Tolerated Dose</subject><subject>Medical Oncology - methods</subject><subject>Medical Oncology - trends</subject><subject>Medical sciences</subject><subject>Models, Biological</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqFj71PwzAQxS0EoqUwM4G8MKb1R2zHY1XxUanQDmW2HNuhqdIksgNV_3tSJbQj0-nd_d7dPQDuMRpjRJNJ2I5NUTdjjlEr6QUYYkZJxBlll2CIEJKRJJQPwE0I21bGMkmuwQALyQRO2BCQD7eHU6vrJv9x8N01m8rCrPJwtdHBwTlc-1wXAeYlXJamKqqvwy24ytqWu-vrCHy-PK9nb9Fi-TqfTReRoZLRyNo4cdKkRkvLORUiFRoLwR0RSSaYZphwnaYkNsYQLDVOsERZbKxkzljE6QhMur3GVyF4l6na5zvtDwojdUyvwlYd06s-fet47Bz1d7pz9sz3cVvgqQd0MLrIvC5NHk4cQTEXmMuWEx23zwt3-O-umq3W5xceOmepm2_vTta_-S8dtH1X</recordid><startdate>200806</startdate><enddate>200806</enddate><creator>Meille, C</creator><creator>Gentet, JC</creator><creator>Barbolosi, D</creator><creator>André, N</creator><creator>Doz, F</creator><creator>Iliadis, A</creator><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200806</creationdate><title>New Adaptive Method for Phase I Trials in Oncology</title><author>Meille, C ; Gentet, JC ; Barbolosi, D ; André, N ; Doz, F ; Iliadis, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3953-dd48e9cbca9d66377b7a1776e278f75a5126abb24ccc219a18190f4cd95ecd063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Clinical Trials, Phase I as Topic - methods</topic><topic>Clinical Trials, Phase I as Topic - trends</topic><topic>Humans</topic><topic>Maximum Tolerated Dose</topic><topic>Medical Oncology - methods</topic><topic>Medical Oncology - trends</topic><topic>Medical sciences</topic><topic>Models, Biological</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meille, C</creatorcontrib><creatorcontrib>Gentet, JC</creatorcontrib><creatorcontrib>Barbolosi, D</creatorcontrib><creatorcontrib>André, N</creatorcontrib><creatorcontrib>Doz, F</creatorcontrib><creatorcontrib>Iliadis, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meille, C</au><au>Gentet, JC</au><au>Barbolosi, D</au><au>André, N</au><au>Doz, F</au><au>Iliadis, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Adaptive Method for Phase I Trials in Oncology</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2008-06</date><risdate>2008</risdate><volume>83</volume><issue>6</issue><spage>873</spage><epage>881</epage><pages>873-881</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><coden>CLPTAT</coden><abstract>Assessment of the maximum tolerated dose for a small sample of patients is the objective of phase I trials in oncology. We propose a new adaptive approach performing differentiation of each type of toxicity and their grades, definition of the dose‐limiting toxicity as a logical combination of toxicity events, modeling of the risk of toxic events as a function of the drug dose, and integration of individual covariates. An application study with retrospective data from a phase I Taxol pediatric trial revealed age as an influential covariate, allowing individualization of a patient's maximum tolerated dose. A simulation study illustrates the practice of sequential inclusion of patients, of constraints in the dose‐finding process and of trial stopping rules. The approach presented here allows quick maximum tolerated dose assessment with a small sample of patients and assists the design of phase I trials in oncology. Clinical Pharmacology &amp; Therapeutics (2008); 83, 6, 873–881 doi:10.1038/sj.clpt.6100383</abstract><cop>New York, NY</cop><pub>Nature Publishing</pub><pmid>17957185</pmid><doi>10.1038/sj.clpt.6100383</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-9236
ispartof Clinical pharmacology and therapeutics, 2008-06, Vol.83 (6), p.873-881
issn 0009-9236
1532-6535
language eng
recordid cdi_crossref_primary_10_1038_sj_clpt_6100383
source Wiley-Blackwell Read & Publish Collection
subjects Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Clinical Trials, Phase I as Topic - methods
Clinical Trials, Phase I as Topic - trends
Humans
Maximum Tolerated Dose
Medical Oncology - methods
Medical Oncology - trends
Medical sciences
Models, Biological
Pharmacology. Drug treatments
Retrospective Studies
title New Adaptive Method for Phase I Trials in Oncology
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A15%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Adaptive%20Method%20for%20Phase%20I%20Trials%20in%20Oncology&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Meille,%20C&rft.date=2008-06&rft.volume=83&rft.issue=6&rft.spage=873&rft.epage=881&rft.pages=873-881&rft.issn=0009-9236&rft.eissn=1532-6535&rft.coden=CLPTAT&rft_id=info:doi/10.1038/sj.clpt.6100383&rft_dat=%3Cwiley_cross%3ECPT6100383%3C/wiley_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3953-dd48e9cbca9d66377b7a1776e278f75a5126abb24ccc219a18190f4cd95ecd063%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/17957185&rfr_iscdi=true